Integra LifeSciences Announces Second Quarter 2004 Financial Results
PLAINSBORO, N.J., July 27, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported net income of $7.5 million, or $0.24 per share, for the second quarter of 2004, compared to net income of $5.4 million, or $0.18 per share, in the second quarter of 2003, a 33% increase in earnings per share over the prior year period.
Total revenues in the second quarter of 2004 increased by $13.7 million to $56.4 million, a 32% increase over the second quarter of 2003, as product revenues increased by $15.2 million to $56.4 million and other revenues decreased by $1.5 million.
Excluding recently acquired product lines, second quarter 2004 product revenues increased by $11.0 million, or 27%, over the prior year period.
Operating income for the period was $11.6 million, a 40% increase over the second quarter of 2003.
"I am pleased with our performance in the second quarter," said Stuart M. Essig, Integra's President and Chief Executive Officer. "In particular, our organic revenue growth exceeded our expectations this quarter, with particularly strong performances from the DuraGen® and DuraGen Plus™ products, the INTEGRA® Dermal Regeneration Template and the INTEGRA™ Bilayer Matrix Wound Dressing. JARIT® also had a very strong quarter, leading our instrument revenues to 20% organic growth versus the prior year period. We also completed two acquisitions during the quarter, which enhanced our neurosurgical product offerings and our distribution capabilities outside the United States."
In May we acquired the MAYFIELD® Cranial Stabilization and Positioning Systems and the BUDDE® Halo Retractor System from Schaerer Mayfield USA, Inc. (formerly Ohio Medical Instrument Company). The acquired operations include a facility located in Cincinnati, Ohio that manufactures, packages and distributes MAYFIELD and BUDDE stabilization products, as well as a broad line of related instruments and disposables used in many neurosurgical and spinal procedures. We market these products through our Integra NeuroSciences sales force.
In May we also acquired Berchtold Medizin-Elektronik GmbH, now named Integra ME, from Berchtold Holding GmbH. Based in Tuttlingen, Germany, Integra ME manufactures and markets the ELEKTROTOM® line of electrosurgery generators and the SONOTOM™ ultrasonic surgical aspirator, as well as a broad line of related handpieces, instruments and disposables used in many surgical procedures, including neurosurgery. We market these products to hospitals and physicians primarily through a network of distributors.
Our revenues for the periods were as follows:
Three Months Six Months Ended June 30, Ended June 30, 2004 2003 2004 2003 -------- -------- -------- -------- Product Revenue: Neuromonitoring products $ 11,813 $ 10,552 $ 23,011 $ 21,084 Operating room products 19,412 12,833 37,744 25,421 Instruments 19,006 12,358 35,049 18,605 Private label products 6,205 5,494 12,068 11,257 -------- -------- -------- -------- Total Product Revenue 56,436 41,237 107,872 76,367 Other revenue 5 1,499 1,013 3,149 -------- -------- -------- -------- Total Revenue $ 56,441 $ 42,736 $108,885 $ 79,516
Increased sales of our intracranial monitoring products and drainage systems provided most of the year-over-year growth in neuromonitoring product revenues.
Continued strong growth in sales of our DuraGen® and DuraGen Plus™ Dural Graft Matrix products and direct selling of the INTEGRA® Dermal Regeneration Template accounted for the increase in operating room product revenues.
Sales of recently acquired product lines contributed $4.2 million of the year-over-year increase in instrument revenues for the second quarter. Increased sales of our JARIT® and Ruggles™ surgical instrument lines and of our ultrasonic aspirator products contributed the remainder of the growth in instrument product revenues.
The increase in our private label product revenues attributable to the Absorbable Collagen Sponge that we supply for use in Medtronic's INFUSE™ bone graft product more than offset the removal of INTEGRA Dermal Regeneration Template revenues from this category.
Changes in foreign currency exchange rates contributed $0.5 million to our year-over-year product revenue growth.
Gross margin on product revenues in the second quarter of 2004 was 62%. Our gross margin was positively affected by changes in the mix of our products sold during the quarter and by the resumption of direct sales of the INTEGRA Dermal Regeneration Template.
Research and development expense decreased slightly from $2.8 million in the second quarter of 2003 to $2.6 million in the current period. Sales and marketing expense increased by $4.1 million to $13.2 million in the second quarter of 2004. This increase was due to the continued expansion of the Integra NeuroSciences and the Integra Plastic and Reconstructive Surgery U.S.-based sales forces, increased marketing headcount and spending particularly to support plastic and reconstructive surgery product lines, and additional spending to support the MAYFIELD and Berchtold product lines. General and administrative expense increased $1.6 million in the second quarter of 2004 to $6.3 million.
We reported net interest income of $160,000 in the second quarter of 2004, as compared to net interest expense of $198,000 in the prior year period.
The Company generated $9.7 million in cash flows from operations in the second quarter of 2004.
The Company's cash and investments totaled $194 million at June 30, 2004.
In the second half of 2004, we expect to incur approximately $1.5 million of charges as a result of the Mayfield acquisition, including inventory fair value purchase accounting costs, facilities consolidation expenses, and distributor termination payments, and related to the planned relocation of our National Distribution Center from Plainsboro, New Jersey to Reno, Nevada in the fourth quarter. We have revised our guidance for the third and fourth quarters of 2004 to reflect these additional anticipated expenses.
In addition, our revised guidance excludes the impact of the $14.9 million after-tax non-cash compensation charge related to the contract stock units granted in connection with the renewal of our Chief Executive Officer's employment agreement in the third quarter of this year. Our guidance also excludes a potential in-process research and development charge related to a $1.5 million milestone payment that may become due in connection with a product development agreement.
Finally, in accordance with our usual practice, our expectations for 2004 and 2005 financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed.
We are updating our expectations for revenues, gross margin and earnings per share for 2004 and 2005. We expect total revenues of between $227 million and $232 million in 2004 and $270 million and $280 million in 2005. Consolidated gross margin is expected to be 61% and 63% of product revenues in 2004 and 2005, respectively. We expect our earnings to be within a range of $1.05 to $1.10 per share in 2004 and $1.42 and $1.47 per share in 2005. Our guidance for the third quarter of 2004 is for total revenues in the range of $58 million to $60 million and earnings per share of $0.26 to $0.28.
We have scheduled a conference call for 9:00 am EDT tomorrow, July 28, 2004, to discuss the financial results for the second quarter of 2004 and forward-looking financial guidance. The call is open to all listeners and will be followed by a question and answer session. Access to the live call is available by dialing (973) 582-2732 or through a listen-only webcast via a link provided on the home page of Integra's website at www.Integra-LS.com. A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through August 11, 2004 by dialing (973) 341-3080 (access code 4865967) or through the webcast accessible on our home page.
Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have research, manufacturing and distribution facilities located throughout the world. We have approximately 1,100 employees. Please visit our website at (http://www.Integra-LS.com).
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, gross margins, earnings per share and cash flows. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, our ability to maintain relationships with customers of acquired entities, physicians' willingness to adopt our recently launched and planned products and our ability to secure regulatory approval for products in development may adversely affect our future product revenues; our ability to increase sales and product volumes may adversely affect our future gross margins; our ability to integrate acquired businesses, increase product sales and gross margins, and control non-product costs may affect our earnings per share; and our future net income results and our ability to effectively manage working capital may affect our future cash flows. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Regulation G, "Conditions for Use of Non-GAAP Financial Measures," and other provisions of the Securities Exchange Act of 1934, as amended, define and prescribe the conditions for the use of certain non-GAAP financial information. In this news release, we provide "growth in product revenues excluding recently acquired product lines", which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most comparable GAAP measure is provided in the tables of financial information contained at the end of this news release.
Non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. Management believes that this non-GAAP financial measure is important supplemental information to investors which reflects an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations, provides a more complete understanding of factors and trends affecting our ongoing business and operations. Management strongly encourages investors to review our financial statements and filed reports in their entirety and to not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONSOLIDATED FINANCIAL RESULTS (In thousands, except per share data) (UNAUDITED)
Statement of Operations Data: Three Months Six Months Ended June 30, Ended June 30, 2004 2003 2004 2003 ------- ------- -------- -------
Product revenues $56,436 $41,237 $107,872 $76,367 Other revenues 5 1,499 1,013 3,149 ------- ------- -------- ------- Total revenues 56,441 42,736 108,885 79,516
Cost of product revenues 21,665 17,090 41,666 30,793 Research and development 2,639 2,777 5,462 5,427 Sales and marketing 13,160 9,082 24,311 16,658 General and administrative 6,328 4,736 12,185 9,570 Amortization 1,049 762 1,932 1,339 ------- ------- -------- ------- Total costs and expenses 44,841 34,447 85,556 63,787
Operating income 11,600 8,289 23,329 15,729
Interest income (expense), net 160 (198) 217 578 Other income (expense), net 135 451 118 800 ------- ------- -------- -------
Income before income taxes 11,895 8,542 23,664 17,107
Provision for income taxes 4,377 3,124 8,708 6,251 ------- ------- -------- -------
Net income $ 7,518 $ 5,418 $ 14,956 $10,856
Diluted earnings per share $ 0.24 $ 0.18 $ 0.48 $ 0.36
Diluted weighted average common shares outstanding 30,964 30,061 30,911 30,463
Condensed Balance Sheet Data: June 30, December 31, 2004 2003 -------- -------- Cash and marketable securities, including non-current portion $194,250 $206,743 Accounts receivable, net 35,622 28,936 Inventory, net 50,509 41,046 Total assets 433,577 412,526
Current liabilities 23,184 20,618 Long-term debt 118,336 119,257 Total liabilities 147,128 143,996
Stockholders' equity 286,449 268,530
Reconciliation of non-GAAP financial measure to the most comparable GAAP measure:
Growth in product revenues excluding recently acquired product lines
Excluding recently acquired product lines, second quarter 2004 product revenues increased by $11.0 million, or 27%, over the prior year period.
Quarter Ended Increase June 30, (Decrease) 2004 2003 $ % ------- ------- ------- ------- ($ in thousands) Total product revenues, as reported $56,436 $41,237 $15,199 37% Less: Product revenues acquired in 2004 and 2003 4,230 -- 4,230 NM ------- ------- ------- ------- Product revenues excluding acquired products $52,206 $41,237 $10,969 27%
"MAYFIELD" is a registered trademark of SM USA, Inc., a wholly owned subsidiary of Schaerer Mayfield USA, Inc.
CONTACT: Integra LifeSciences Holdings Corporation
John Bostjancic Maria Platsis Senior Director of Finance Director of Corporate Development (609) 936-2239 and Investor Relations jbostjancic@integra-ls.com (609) 936-2333 mplatsis@integra-ls.com